# Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm

> **NCT02947815** · PHASE2,PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 234 (estimated)

## Conditions studied

- Blepharospasm

## Interventions

- **DRUG:** Clostridium Botulinum Toxin Type A
- **DRUG:** Clostridium Botulinum Toxin Type A

## Key facts

- **NCT ID:** NCT02947815
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947815, "Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02947815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*